Compare Agilent Technologies Inc (A) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Plby Group Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Plby Group Inc trades at $1.34 (market cap $139.87M). The key difference: Agilent Technologies Inc is far larger — about 300.3× Plby Group Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| A | PLBY | |
|---|---|---|
Market Cap | $42.00B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $2.71 |
52-Week Low | $110.24 | $1.11 |
Enterprise Value | $43.55B | $287.68M |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
PLBY trades at $1.22, up 5.17% today, amid a bearish technical signal with moving averages indicating selling pressure. The company reported Q2 2026 revenue growth and positive operating cash flow, with a net income margin improving to -6.21% in 2026 from -10.48% in 2025. Recent developments include inclusion in the Russell 2000 index and a share repurchase program, while debt-to-asset ratio remains elevated at 59.52% as of 2025.
The outlook is mixed: analyst consensus is 75% buy with potential from brand licensing growth, but high debt and persistent net losses pose risks. Investors should weigh the improving EBITDA trend against negative equity and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
